Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Circulating Tumor Cells in Precision Oncology
share announcement

Circulating Tumor Cells in Precision Oncology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 7936

Special Issue Editors

Prof. Dr. Nikolas H. Stoecklein

E-Mail Website
Guest Editor
Faculty of the Heinrich‐Heine, General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty, University Düsseldorf, Düsseldorf, North Rhine‐Westphalia, Germany
Interests: ctc; single cell analysis
Dr. Andreas Josefsson

E-Mail Website
Guest Editor
Department of Surgical and Perioperative Sciences, Umeå universitet, Umeå, Sweden
Interests: CTC; prostate cancer

Special Issue Information

Dear Colleagues,

Liquid biopsy companion diagnostics for precision oncology have become a clinical reality and are currently based on the detection and analysis of freely circulating tumor DNA. With few exceptions, the "classic" liquid biopsy biomarker, circulating tumor cells (CTCs), has not found its way into clinical routine yet, despite decades of research. However, recent technical developments have paved the way for CTC-based molecular diagnostics. The advantage of CTCs compared to other blood-based biomarkers is their versatility. As surrogates for cancer tissue, they can provide clinically relevant information at the protein, RNA, and/or DNA levels. Several promising approaches have been established to enable comprehensive molecular CTC profiling even at the single-cell level, but technical challenges remain, such as assay efficiency and reproducibility. The focus of this Special Issue of Cancers is on aspects of CTC characterization with potential utility for precision medicine and on how new technical advances can address the current limitations. Also of great interest are reports on how CTCs can be compared or complemented with other liquid biopsies. This Special Issue welcomes contributions that address and discuss the advantages and disadvantages of CTCs for precision medicine in all cancers. The goal of this Special Issue is to highlight CTCs alone or in combination with other analytes as a clinical tool for precision medicine, as well as to discuss their potential as a means to identify new mechanisms of the metastatic and drug resistance processes. The overall goal is to promote the field of liquid biopsies so to make this technique a clinically valuable tool for better treatment of cancer patients. 

Prof. Dr. Nikolas H. Stoecklein
Dr. Andreas Josefsson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • circulating tumor cells (CTCs)
  • liquid biopsies
  • single cell analysis
  • detect
  • mechanism

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 2851 KiB  
Article
Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing
by Masahiro Kozuka, Francesca Battaglin, Priya Jayachandran, Jingyuan Wang, Hiroyuki Arai, Shivani Soni, Wu Zhang, Mitsuharu Hirai, Satoshi Matsusaka and Heinz-Josef Lenz
Cancers 2021, 13(19), 4862; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13194862 - 28 Sep 2021
Cited by 8 | Viewed by 4762
Abstract
Background: Circulating tumor cells (CTCs) are a prognostic marker in patients with metastatic colorectal cancer (mCRC). However, little is known about the characterization of CTCs in mCRC at the single-cell level using RNA sequencing. The purpose of this study was to validate the [...] Read more.
Background: Circulating tumor cells (CTCs) are a prognostic marker in patients with metastatic colorectal cancer (mCRC). However, little is known about the characterization of CTCs in mCRC at the single-cell level using RNA sequencing. The purpose of this study was to validate the capability to detect and isolate single CTCs for single-cell RNA sequencing (scRNA-seq) and to identify clinical significance at a single CTC level. Methods: Single CTCs from 27 mCRC patients were collected by CTC-FIND, which is comprised of filter separation and immunomagnetic depletion to collect ultra-pure CTC samples. To address tumor heterogeneity, CTCs were collected without relying on any traditional CTC markers, such as epithelial and mesenchymal cell antigens, and were undertaken by scRNA-seq using SMART-Seq v4. Results: We identified 59 single CTCs which were classified into four groups by epithelial, epithelial-mesenchymal transition (EMT) and stem cell-related gene expression. Patients receiving second or later-line treatment who had EMT gene expressing CTCs had a significantly shorter PFS and OS. Conclusions: Exploiting CTC-FIND with SMART-Seq v4 showed that scRNA-seq of CTCs may shed new insight into tumor heterogeneity of mCRC and that the presence of CTCs expressing EMT-related genes at the single-cell level could have prognostic value in mCRC patients. Full article
(This article belongs to the Special Issue Circulating Tumor Cells in Precision Oncology)
►▼ Show Figures

Figure 1

Other

Jump to: Research

14 pages, 1250 KiB  
Systematic Review
Circulating Tumor Cells as a Predictive Biomarker in Resectable Lung Cancer: A Systematic Review and Meta-Analysis
by Durgesh Wankhede, Sandeep Grover and Paul Hofman
Cancers 2022, 14(24), 6112; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14246112 - 12 Dec 2022
Cited by 14 | Viewed by 2182
Abstract
Background: In breast, prostate, and other epithelial tumors, circulating tumor cells (CTC) in peripheral blood may predict survival. Our study evaluated the prognostic significance of baseline and postoperative CTC in patients with early non-small cell lung cancer (NSCLC) through a meta-analytic approach. Methods: [...] Read more.
Background: In breast, prostate, and other epithelial tumors, circulating tumor cells (CTC) in peripheral blood may predict survival. Our study evaluated the prognostic significance of baseline and postoperative CTC in patients with early non-small cell lung cancer (NSCLC) through a meta-analytic approach. Methods: Prospective studies comparing survival outcomes between positive (CTC+) and negative CTC (CTC−) patients were systematically searched. Primary outcomes were overall (OS) and disease-free survival (DFS) with hazard ratio (HR) and 95% confidence interval (CI) as the effect measure. Pooled HR determined the prognostic role under a fixed-effect or random-effect model depending on heterogeneity. Results: Eighteen studies with 1321 patients were eligible. CTC+ patients were associated with an increased risk of death (HR 3.53, 95% CI 2.51–4.95; p < 0.00001) and relapse (HR 2.97, 95% CI 2.08–4.22; p < 0.00001). Subgroup analysis results were consistent in different subsets, including time points (baseline and postoperative) and sources (peripheral and pulmonary vein) of blood collection, detection methods (label-free, label-dependent, and RT-PCR), and follow-up duration. Conclusion: Our meta-analysis revealed that CTC is a promising predictive biomarker for stratifying survival outcomes in patients with early-stage NSCLC. However, future studies are required to validate these findings and standardize detection methods. Full article
(This article belongs to the Special Issue Circulating Tumor Cells in Precision Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop